anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A preparation for the treatment of cancer &amp;c. is obtained by treating metochondrial animal material selected from the liver, kidney or heart in such a way that the enzymes are liberated, and dialysing the disintegrated material to obtain a dialysate containing the co-enzymes of the succin-oxydase system having a particle size smaller than 10 m .  Thus, liver is frozen, finely ground and dried in vacuo, the powder is stirred with a fat-dissolving organic solvent, e.g. butanol-1, filtered, and the residue dried.  This is mixed with water or physiological salt solution, and dialyzed using a membrane of pore width 5-10 m  against water or physiological salt solution at 0-2 DEG  C. Concentration may be effected by dialysing new starting material against a dialysate already prepared.  The preparation may be sterilized by ultrafiltration in vacuo.  The operations generally, and storage, are effected under nitrogen.ALSO:A preparation for the treatment of cancer &amp;c. is obtained by treating initochoudrial animal material selected from the liver, kidney or heart in such a way that enzymes are liberated, and dialyzing the disintegrated material to obtain a dialyzate containing co-enzymes of the succinoxydase system having a particle size smaller than 10m . Thus, liver is frozen, finely ground and dried in vacuo, the powder is stirred with a fat-dissolving organic solvent, e.g. butanol-1, filtered, and the residue dried.  This is mixed with water or physiological salt solution, and dialyzed by means of a membrane of pore width 5-10m  against water or physiological salt solution at 0-2 DEG C. Concentration may be effected by dialyzing new starting material against a dialyzate already prepared.  The preparation may be sterilized by ultra filtration in vacuo.  The operations generally, and storage, are effected under nitrogen.
The present invention provides a membrane the conductivity of which is dependent on the presence or absence of an analyte.  The membrane comprises a closely packed array of self-assembling amphiphilic molecules and two ionophore components.  A receptor molecule reactive with the analyte is provided on one of the ionophore components.  The binding of the analyte to the receptor molecule causes a change in the relationship between the ionophore components such that the flow of ion across the membrane is prevented or allowed.  The ionophore components are preferably selected from the group consisting of amphotericin B, gramicidin A monomers and combinations thereof, with gramicidin A monomers being particularly preferred.  The present invention also provides a membrane including receptors directed against the Fc region of antibodies.  These receptors are preferably derived from polyclonal antibodies.  These membranes provide a &#34;generic&#34; surface which will bind antibodies in a manner such that the antigen binding regions of the antibody are not hindered.  The present invention further provides a device adapted for implantation in a mammalian body, the device being characterised in that it is coated with a membrane comprising a closely packed array of self-assembling amphiphilic molecules and receptor molecules.  The receptor molecules being such that the attachment of specific cells to the membrane is enhanced or avoided.  It is particularly preferred that the receptor molecules are directed against fibronectin, vitronectin, endothelial cells, or epithelial cells.  It is further preferred that the membrane coating the device also includes a plurality of ion channels such as gramicidin.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an implantable device which can convey a therapeutic agent to tissue or organs for a long period of time.  &lt;P&gt;SOLUTION: The device is a cylinder 10 including a wall 20 which does not exhibit penetratability into giant molecules like proteins and cells. The cylinder wall 20 may be made of silicon of a medical grade, stainless steel, titanium or plastic. A biodegradable matrix 30 and the therapeutic agent intimately mixed therewith are packed into the cylinder 10. Terminals 15 and 17 of the cylinder 10 are opened toward the tissue.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
The invention relates to a traditional Chinese medicine composition for treating functional constipation and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines: radix Paeoniae alba, Atractylodis rhizoma, radix rehmanniae, fructus Aurantii Immaturus parched with bran, cortex Magnolia officinalis, and fructus Cannabis. The invention also provides application of the traditional Chinese medicine in preparing a medicine for treating functional constipation. Its advantages are: 1. the selected raw material medicines are appropriate in cold and warm, and appropriate in moistening dryness, and are communicated with the tonifying, so that the effects of tonifying spleen, clearing heat, nourishing yin, moistening dryness, promoting qi circulation and clearing hollow viscera are achieved. 2. The compatibility of the traditional Chinese medicine composition for treating functional constipation conforms to the principle of &#39;monarch, minister, assistant and guide&#39; of traditional Chinese medicines, and the traditional Chinese medicine composition has the advantages of fewer medicine ingredients, high curative effect, no toxic or side effect, low cost and the like. 3. The selected raw material medicines and the proportion thereof are screened by tests, and the invention has the advantage of remarkable effect. 4. The traditional Chinese medicine composition can effectively improve constipation symptoms of functional constipation (intestinal excess heat syndrome), traditional Chinese medicine symptoms and life quality, is safe to apply in a short term, and has low adverse reaction.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an effective and safe anti-viral agent capable of being applied to fields such as medicines, cosmetics, foods, cleansers, daily necessaries, fibers, coatings, and resins, and to provide an anti-viral composition.  &lt;P&gt;SOLUTION: Provided are the antiviral agent comprising polyglycerol having a weight-average mol.wt. of 1,000 to 7,000; and the antiviral composition. The polyglycerol is preferably a branched polyglycerol. The preparations such as medicines, cosmetics, foods, cleansers, daily necessaries, fibers, coatings, and resins concretely include medicines such as gargles, nasal drops, and common cold medicines; cosmetics such as make-up creams, face-washing agents, body soaps, and hand soaps; hair cosmetics such as shampoos and rinses; foods such as candies, gummy candies, and drinking water; cleansers such as cleansers for vegetables or dishes, detergents for clothing, and softeners; daily necessaries such as masks, tissue paper, and gloves; fiber products such as fiber products for wiping up bodies or articles impregnated with liquids; coatings such as paints and lacquers; resins and the like.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a refreshing composition or a composition for mucosa application (eye drop) which can increase and keep a refreshing feeling in a composition containing a refreshing component. SOLUTION: This refreshing composition is obtained by combining a compound (e.g. caffeine, etc.), represented by formula (1) (R&lt;1&gt; , R&lt;2&gt; and R&lt;3&gt; are each a hydrogen atom or an alkyl group which may be substituted) or its salt with a refreshing component (menthol, camphor, borneol, etc.). Consequently, the refreshing feeling of the refreshing component can be continued by the compound represented by formula (1) or its salt. Further, the compound represented by formula (1) can continue the refreshing feeling by the refreshing component while raising the refreshing feeling. The ratio of the compound (1) or its salt is about 0.1-1,000 parts wt. in terms of a free compound based on 1 part wt. of the refreshing component.  The refreshing composition can be used as a composition for mucosa application (solution such as eye drop, eye wash, nasal drop, agent for contact lens, etc., and an ointment such as eye ointment, etc.).
PURPOSE:To obtain a remedy for nephritis having excellent remedying effect against nephritis and exhibiting little side effect by using an acidic heteropolysaccharide produced by the tissue culture of a plant as an active component. CONSTITUTION:The objective agent is produced by using an acidic heteropolysaccharide secreted from the cell of a callus induced from a plant of genus Polianthes (e.g. tuberose) as an active component, properly mixing with a pharmacologically allowable additive and forming in the form of medicine by conventional method. The acidic heteropolysaccharide contains arabinose, mannose, galactose, glucuronic acid and xylose as constituent sugars and the bonding patterns and the constitution ratios of the sugars are shown in the formula. The molecular weight of the polysaccharide is 1X10&lt;4&gt; to 2X10&lt;7&gt;. It can be used as injection, tablet, powder, granule, capsule, etc., and is administered at rate of 1-20mg for injection and 10-200mg for oral administration for male adult per week.
PURPOSE: To obtain a composition for controlling the color of skin, capable of changing a deep color part such as a stain or a freckle into an inconspicuous color part by compounding a substance having a yellow-red color interference color. CONSTITUTION: A substance having a yellow-red interference color is compounded in an amount of &gt;=2wt.%, preferably &gt;=10wt.%, based on the whole powder amount in the composition. The substance having the yellow-red interference color is preferably mica covered with a titanium dioxide-having titanium compound layer having an optical film thickness of 190-270nm and/or an optical film thickness of 410-500nm layer. In particular the titanium compound layer preferably contains titanium oxide nitride and/or a lower grade titanium oxide. The composition can change a deep skin color into an inconspicuous skin color in a natural form without deteriorating the transparent appearance of the skin.  The employment of the mica titanium containing the titanium oxide nitride and/or the low grade titanium oxide can give a finish appearance which is free from a brightness due to the luster of a pearl agent, which is a natural transparent appearance, and in which the deep color skin part has a color substantially equal to that of a normal color part.
A compound of the formula  &lt;IMAGE&gt;  is disclosed. X is selected from the group consisting of aryl, alkyl, imidate ester, imino ester, amidine, azide, isocyanate, and dithiocarbonate. R&#39; is a group selected from the group consisting of groups containing a hydroxyl moiety, groups containing a protected hydroxyl moiety, and groups containing an O-linked sugar. G is a carbon chain of 0-10 carbons and R is not a methyl group and is a group capable of removal under conditions compatible with glycopeptide synthesis. In a preferred form the compound, R is selected from the group consisting of benzylic or allyl groups and X is CPh2. A method of forming a glycocide from the compound is also disclosed.
1378212 Polymeric denture bases AMALGAMATED DENTAL CO Ltd 9 March 1973 [15 March 1972] 12135/72 Heading C3P A denture base is formed from a copolymer of an ester of trialkyl tin and an ethylenically unsaturated carboxylic acid and one or more other ethylenically unsaturated comonomers. The acid is preferably acrylic or methacrylic acid thus giving an ester of the formula in which R is a C 1-6  alkyl group and R&lt;SP&gt;1&lt;/SP&gt; is H or -CH 3 . Examples of the monomer are tributyl tin methacrylate and trimethyl tin methacrylate. Two of the tin monomers may be present, one of which is trimethyl tin methacrylate. The comonomer may be a C 1-6  alkyl methacrylate or acrylate or a C 8-20  alkyl acrylate or methacrylate or a mixture of these. A polyethylenically unsaturated cross-linking monomer may also be present, such as a diacrylate or dimethacrylate of a dihydric alcohol. The denture base is formed by mixing the copolymer with one or more other ethylenic monomers into a dough, placing this in a mould or dental flask, and curing. The invention also comprises a two part pack one of which contains a finely divided tin containing copolymer of a tin compound as defined above together with one or more other ethylenically unsaturated monomers, and the other pack contains one or more liquid ethylenically unsaturated monomers. In the example methylmethacrylate, tributyl tin methacrylate and trimethyl tin methacrylate are copolymerized to form a finely divided copolymer. This is then mixed with a liquid mixture of lauryl methacrylate, methyl methacrylate and ethylene glycol dimethacrylate and the mixture cured in a dental mould.
PURPOSE:To obtain the subject composition applicable to a wide variety of drugs and having controllable digestibility in body by including a drug in a matrix composed of a chemically crosslinked chitosan derivative soluble in water and organic solvent and acetylating residual amino group. CONSTITUTION:The objective drug composition can be produced by adding a drug to a solution of a chitosan derivative soluble in water and organic solvent (e.g. a hydroxyalkylchitosan derivative having an average molar number of added alkylene oxide of &gt;=1 and produced by etherifying chitin and chitosan with an alkylene oxide), adding a crosslinking agent (e.g. dialdehyde or dicyanate), stirring the obtained mixture, crushing the formed gel, adjusting the particle diameter of the crushed gel, suspending in a solvent such as ethanol and acetylating the product. Since the drug can be included in neutral state or in an organic solvent, a drug susceptible to acid can be used. The digestibility in the body can be controlled by controlling the crosslinking degree and acetylation degree.
PROBLEM TO BE SOLVED: To efficiently obtain a stable dissolved material of a lipophilic material for a short time by treating a cyclodextrin(CD) and the lipophilic material by a wet jet mill. SOLUTION: Though the lipophilic material is not restricted, particularly, vitamin E, soybean oil, docosa-hexaenoic acid and the like are cited. As the cyclodextrin(CD), at least one kind selected from the group of α-, β- and γ-CD composed of respectively 6 molecules, 7 molecules and 8 molecules of glucose, their sugar modified materials and chemically modified materials is cited. In the addition of the CDs, the one combined with at least one kind selected from the group composed of the sugar modified materials and the chemically modified materials obtained by replacing at least &gt;=1 of these hydroxyl group with at least &gt;=1 of functional groups can be used. When producing a clathrate compound of CD with the lipophilic material, the wet jet mill is used for the process. As a result, the excellently stable dissolved material is efficiently produced for a short time.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medicine notebook system which eliminates the troublesomeness of managing a medicine notebook for a patient and enables a pharmacist to give an appropriate advice based on medication history information to the patient.  &lt;P&gt;SOLUTION: In a data base, a storage area for patient data including patient identification information and the attribute information of the patient and a storage area for prescription data are secured. The prescription data are stored corresponding to the patient data of the patient to whom a prescription specified by the prescription data is given. A controller receives the patient identification information and the prescription data of medicines prescribed to the patient from a pharmacy information terminal arranged in each pharmacy. In the case that the patient identified by the received patient identification information is already registered in the data base, the received prescription data are stored corresponding to the patient data. In the case that the patient is not registered in the data base, the patient data of the patient are added to the data base and also the received prescription data are stored corresponding to the added patient data.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The present invention relates to a common cold medicine effervescent tablet and a preparation method thereof. The common cold medicine effervescent tablet has the advantages of portability, good mouth feel and fast release, and comprises active ingredients and effervescence acid-base pairs, wherein the active ingredients are paracetamol, amantadine hydrochloride, caffeine, artificial bezoar and chlorpheniramine. The formability and the effervescence property of the effervescent tablet can be improved through the selection of acid and alkali pairs and suitable medicinal auxiliary materials are complemented. The release speed of the medicine is enhanced, the taste is corrected, and the common cold medicine effervescent tablet is particularly suitable for a child patient to use; simultaneously, an adult&#39;s resistance can also be greatly enhanced. The present invention reduces the harsh requirement for environment in the process of preparation, and the effervescent tablet can also be easily made even under high humidity conditions. The tablet weight of each optimized tablet is from 100 mg to 5000 mg.
PURPOSE:To separate a polyprenyl compound or its mixture useful as a synthetic raw material of dolichols having extremely important functions for life maintenance, from the extract obtained by extracting the leaves of Himalayan cedar with an organic solvent. CONSTITUTION:The leaves of Himalayan cedar are extracted with an organic solvent (e.g. hydrocarbons, ethers, etc.) and the extract is if necessary hydrolyzed, and subjected to the thin-layer chromatography using a 9:1 (vol ratio) mixture of n-hexane and ethyl acetate as the developing solvent. In the above chromatography, the fraction exhibiting the Rf value of 0.18-0.25 and/or 0.50- 0.55 under the condition that the Rf value of solanesyl acetate used as the standard substance becomes 0.40-0.45, is separated and recovered to obtain the titled substance containing the compounds of formula (A is OH or acyloxy; n is integer of 11-19). The substance contains the compounds of formula wherein n is 14, 15 or 16 as essential components, and the sum of the components is &gt;=70wt%.
The present invention provides double-stranded RNA molecules that mediate RNA  interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer.  The invention provides modified RNA molecules that are modified to include a dsRNA or siRNA wherein one or more of the pyrimidines in the RNA molecule are modified to include 2&#39;-Fluorine. The invention also provides dsRNA or siRNA in which all pyrimidines are modified to include a 2&#39;-Fluorine. The invention provides that the 2&#39;-Fluorine dsRNA or siRNA molecule is further modified to include a two base deoxynucleotide &#34;TT&#34; sequence at the 3&#39; end of the molecule.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a homogeneous and stable retort-sterilized gelatinized nutritive preparation as a fluid diet with protein therein prevented from aggregation and segregation.  &lt;P&gt;SOLUTION: The retort-sterilized gelatinized nutritive preparation essentially contains protein, lipids, carbohydrates, vitamins and mineral(s); wherein the mineral(s) is at least calcium and/or magnesium. This gelatinized nutritive preparation also contains citric acid and/or its salt. A method for producing the gelatinized nutritive preparation is provided, comprising the following process: Water is mixed essentially with the protein, lipids, carbohydrates, vitamins and mineral(s) followed by emulsification to obtain a nutritive preparation, to which a gelatinizer is added, followed by mixing, the resultant nutritive preparation is packed in a container and then retort-sterilized. In this process, the mineral(s) is at least calcium and/or magnesium, and citric acid and/or its salt is added.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
1. A method for preparing an effervescent granulate comprising a pharmacologically active ingredient, and citric acid and sodium bicarbonate as effervescent system, by means of wet granulation in a fluid-bed granulator, comprising the steps of: I. feeding a mixture comprising said active ingredient, citric acid and sodium bicarbonate into the said granulator which is simultaneously fed with a flow of air heated to about 70 degree C(+3 degree C) and having a moisture content of &lt; 1.0 g/kg; II. wetting the said mixture with nebulized water; III. evaporating off the nebulizing water; characterized in that said mixture includes ferrous gluconate (2) as said pharmacologically active ingredient, and said step II is carried out when said mixture has reached a temperature of about 35 degree C(+3 degree C), and in said step III the temperature of said mixture is kept substantially constant at 35 degree C(+3 degree C), the method further comprising the following steps: IV. repeating steps II and III until a granulate with the desired features is obtained; and drying the said granulate with air heated to about 80 degree C(+3 degree C) until its moisture content is &lt;=0.5% by weight, 2. A method according to claim 7, characterized in that, in step I, the magnitude of the air flow rate is between 3200 and 3800 m&lt;3&gt;/hour for each batch of about 265 kg of mixture to be granulated. 3. A method according to claim 1 or 2, characterized in that, in step II, the flow rate of nebulized water is preferably between 500 and 2000 ml/min. 4. A method according to any one of the preceding claims 1 to 3, characterized in that, in step II, the pressure of the flow of nebulized water is about 3 atmospheres. (3 x 1.013 bar). 5. A method according to any of claims 1 to 4, characterized in that tile total amount of water used in step II does not exceed 2% by weight of the mixture to be granulated. 6. A method according to any of claims 1 to 5, characterized in that the amount of nebulized water in each step does not exceed 0.5% by weight of the mass being processed. 7. An effervescent granulate obtained according to any of the preceding claims, comprising from 7 to 35% by weight of ferrous gluconate(2), from 25 to 45% by weight of citric acid and from 15 to 25% by weight of sodium bicarbonate. 8. An effervescent granulate according to claim 7, characterized in that it also comprises from 5 to 18% by weight of sorbitol, about 2% by weight of L-leucine and from 5 to 18% by weight of flavourings. 9. A granulate according to claim 7, characterized in that the ferrous gluconate is in the form of the dihydrate. 10. A tablet obtained by tabletting an effervescent granulate which is obtained according to any one of the preceding claims 1 to 6, the said tablet comprising from 7 to 35% by weight of ferrous gluconate, from 25 to 45% by weight of citric acid, from 15 to 25% by weight of sodium bicarbonate, from 5 to 18% by weight of sorbitol, about 2% by weight of L-leucine and from 5 to 11% by weight of flavourings.